Phase II, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-based anti-Cytomegalovirus (CMV) Vaccine (Triplex?), in Adults with Both Human Immunodeficiency Virus (HIV)-1 and CMV Who Are on Potent Combination ART with Conserved Immune Function

This Study is
No Longer Enrolling

Details
Age

Adult

Type of Study

Treatment

Locations

Outpatient CTRC

Study ID

Protocol Number: 21-4360

More information available at ClinicalTrials.gov: NCT05099965

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers